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Abstract
OBJECTIVES: The study aimed to determine the impact of interstitial lung disease (ILD) on postoperative morbidity, mortality and long-
term survival of patients with non-small-cell lung cancer (NSCLC) undergoing pulmonary resection.
METHODS: We performed a retrospective chart review of 775 consecutive patients who had undergone lung resection for NSCLC
between 2000 and 2009. ILD, defined by medical history, physical examination and abnormalities compatible with bilateral lung fibrosis
on high-resolution computed tomography, was diagnosed in 37 (4.8%) patients (ILD group). The remaining 738 patients were classified
as non-ILD (control group). We also attempted to identify the predictive factors for early and late survival in patients with ILD following
pulmonary resection.
RESULTS: There was no significant difference between the two groups in terms of age (69 vs 66 years), sex (79 vs 72% male), smoking
history (93 vs 90% smokers), forced expiratory volume in 1 s % of predicted (89 vs 84%), predicted values of forced vital capacity
(FVC)% (92 vs 94%), types of surgical resection and histology. Patients with ILD had a higher incidence of postoperative acute respira-
tory distress syndrome (ARDS; 13 vs 1.8%, P < 0.01) and higher postoperative mortality (8 vs 1.4%, P < 0.01). The overall 5-year survival
rate was 52% in the ILD and 65% in the non-ILD patients, respectively (P = 0.019). In the ILD group, at the median follow-up of 26
months (range 4–119), 19 (51%) patients were still alive and 18 (49%) had died in the ILD group. The major cause of late death was re-
spiratory failure due to the progression of fibrosis (n = 7, 39%). In the ILD group, lower preoperative FVC% (mean 77 vs 93%, P < 0.01)
and lower diffusing capacity of the lung for carbon monoxide (DLCO%; 47 vs 62%; P < 0.01) were significantly associated with post-
operative ARDS.
CONCLUSIONS: In conclusion, major lung resection in patients with NSCLC and ILD is associated with an increased postoperative mor-
bidity and mortality. Patients with a low preoperative FVC% should be carefully assessed prior to undergoing surgery, particularly in the
presence of a lower DLCO%. Long-term survival is significantly lower when compared with patients without ILD, but still achievable in
a substantial subgroup. Thus, surgery can be offered to properly selected patients with lung cancer and ILD, keeping in mind the risk of
respiratory failure during the evaluation of such patients.
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survival
INTRODUCTION
The incidence of lung cancer is reported to be higher among
patients who have interstitial lung disease (ILD) compared with
that of the general population [1, 2]. The appropriate selection of
patients with lung cancer and ILD for major lung resection is a
challenge as a consequence of reduced cardiopulmonary
reserve. Although most studies have shown inferior results in
patients with ILD compared with patients without, there is a
wide variation in reported postoperative morbidity and mortality
(ranging from 0 to 18.2%) and also in long-term survival (5-year
survival rate 0–65%) [3–8]. Moreover, the predictors of short- and
long-term survival are not well defined. It is also unknown what
type of ILD carries a higher risk of postoperative morbidity and
mortality.
The aim of this study was to detail our experience with lung
resections for non-small-cell lung cancer (NSCLC) in patients
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with ILD in order to determine the impact of ILD on post-
operative morbidity and mortality and long-term survival. We
also attempted to identify the predictive factors for early and
late survival in patients with ILD following pulmonary resection.
MATERIALS AND METHODS
Population
We performed a retrospective analysis of 775 consecutive
patients operated on for NSCLC at the University Hospital of
Siena from January 2000 to December 2009, in order to identify
all patients also affected by ILD. This 10-year interval was chosen
because the staging tools, surgical techniques, surgical team and
postoperative care did not change during this time frame.
Thirty-seven (4.8%) patients carried a preoperative diagnosis
of ILD, based on medical history, physical examination and ab-
normalities compatible with bilateral lung fibrosis on high reso-
lution computed tomography (HRCT) (honeycombing with basal
and peripheral predominance, peripheral reticular shadow or
ground-glass opacity) and constituted the study group (ILD
group). The remaining 738 patients who did not show any pre-
operative evidence of ILD served as the control group (non-ILD
group). The types of ILD were classified according to recently re-
classified American Thoracic Society/European Respiratory
Society criteria [9].
The Institutional Review Board of the University Hospital of
Siena approved this retrospective study. The patients had under-
gone surgery after providing informed consent, and the need for
individual consent of patients whose records were evaluated was
waived because they were not identified in the study.
Information about preoperative patient characteristics, disease
status, surgical procedures, postoperative complications, patho-
logical findings and outcome of treatment was collected.
Patient selection and management
Assessment included a detailed medical history, physical examin-
ation, routine blood tests, electrocardiogram, echocardiography,
blood gas analysis, spirometry and estimation of the carbon
monoxide diffusion capacity of the lung (DLCO).
Cardiac stress tests and coronary angiography were performed
when indicated by a history of angina pectoris or by significant
ischaemic signs in the basal electrocardiogram; cardiorespiratory
tests and/or lung perfusion scintigraphy were executed as
second level tests in case of the predicted postoperative forced
expiratory volume in 1 s <40%.
Clinical staging was based on bronchoscopy, contrast-enhanced
computed tomography (CT) of the chest, upper abdomen and
brain; mediastinoscopy was carried out selectively in the case of
enlarged mediastinal lymph nodes on CT (short axis >1 cm).
During the study period, the policy of our institution was to
perform lobectomy as the procedure of choice whenever the pre-
dicted postoperative forced expiratory volume in 1 s was >1 l and
the predicted postoperative DLCO was >30% reserving the sublo-
bar resections for patients showing lower respiratory reserve.
The patients in the ILD group who were on steroids and/or
immunosuppressants were given the same dose of steroids
intravenously during the first two or three postoperative days of
coming back to oral administration when an oral diet was
resumed.
Pulmonary resections were performed via either a posterolat-
eral thoracotomy or a lateral muscle-sparing thoracotomy.
During the operation, the lung was kept inflated for as much
time as possible and always during the dissection of fissures.
Systematic lymph node dissection was performed in all patients.
After operation, transfusion was performed at a speed of 1.25
ml/kg/h, and oxygen administration was set at the level to main-
tain a Pulse Oximeter Oxygen Saturation of at least 93.
In our routine daily check-up of postoperative patients, chest
X-ray is undertaken on postoperative days 0, 1, 4 and 7, reserv-
ing the CT scan and bronchoscopy in the case of a decreasing
trend in pO2 and a new infiltrating shadow on chest X-ray.
Postoperative complications
The incidence of postoperative pulmonary complications and
that of hospital mortality (death from all causes during the same
hospitalization or within 60 days of surgery) were analysed and
compared between the ILD and non-ILD groups.
Pulmonary complications included pneumonia, prolonged air
leak, atelectasis requiring bronchoscopy, bronchopleural fistula,
empyema and acute lung injury (ALI)/acute respiratory distress
syndrome (ARDS).
Pneumonia was defined as the presence of focal or diffuse in-
filtrate on chest X-ray associated with one or more of the follow-
ing criteria: fever exceeding 38°C, purulent sputum, leukocytosis
(>10 000/ml) or isolation of a pathogen in respiratory secretions.
Air leakage was defined as prolonged if it lasted for >7 days.
ALI and ARDS were defined according to the American-
European Consensus Conference on ARDS [10].
The final status of all patients was determined in January 2012
on the basis of either the patients’ most recent clinic visit or hos-
pitalization or by means of a telephone interview.
Statistical analysis
Statistical evaluation was performed by standard computer soft-
ware (SPSS 9.0; SPSS, Inc., Chicago, IL, USA). All data are pre-
sented as mean ± standard deviation. Differences in continuous
variables were tested by unpaired Student’s t-test. Differences in
categorical and dichotomic variables were tested by the χ² test
and Fisher’s exact test, respectively.
Survival was defined as an interval between the surgical resec-
tion and death or last contact and was calculated by means of
the Kaplan–Meier method. Patients who were not reported as
having died at the time of analysis were censored at the date
they were last known to be alive (non-informative censoring).
The comparison of survival between groups was made with the
log-rank test.
In patients with ILD, the Cox multivariable proportional
hazard regression model was used to identify the risk factors of
late death. Clinical–pathological-related factors were quantified
by univariable analysis, and all factors with P-values of <0.2 at
univariable analysis were included in the multivariable Cox’
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The preoperative characteristics of all patients subdivided in the
two groups are shown in Table 1. There was no statistically sig-
nificant difference between the two groups in terms of age,
gender, smoking history and preoperative pulmonary function.
The operative procedures were similar in the two groups. In
the ILD group, 4 pneumonectomies, 30 lobectomies and 3 sub-
lobar resections were performed.
The distribution of histological cell type of NSCLC and patho-
logical stages were also similar in the two groups (Table 2).
Twelve patients in the ILD group were on treatment with steroid
and/or immunosuppressive drugs at the time of surgery, and 18
(49%) had a Borg dyspnoea score II–III.
Relative risks in patients with ILD
Patients with ILD showed a significantly longer mean hospital
stay (12 vs 9 days; P < 0.01) and developed postoperative ARDS
more frequently than those without ILD (13.5 vs 2.3%; P < 0.01).
The mean time from the operation to the diagnosis of ARDS was
2.2 ± 2.3 (range 2–5) days.
In the ILD group, the incidence of ARDS after pneumonec-
tomy was 25% compared with 10% after lobectomy, and the
ARDS was the cause of death in all 3 patients who died in the
postoperative period for a hospital mortality of 8.1%. The hos-
pital mortality was more common in patients with ILD than in
patients without ILD (8.1 vs 1.4%; P < 0.01).
The analysis of the outcome related to specific surgical proce-
dures also showed a significantly higher postoperative mortality
for pneumonectomy (25 vs 3.3%; P < 0.01) and lobectomy (6.6 vs
1.3%; P < 0.01) in patients with ILD, compared with patients
without ILD. No patient died after a sublobar resection in the
ILD group (Table 3).
Except for the development of postoperative ARDS, there was
no significant difference between the two groups, in post-
operative pulmonary complications, including pneumonia,
bronchopleural fistula, prolonged air leak and atelectasis requir-
ing bronchoscopy (Table 4).Table 1: Preoperative characteristics of patients with and
without ILD
ILD group (n = 37) Non-ILD
group (n = 738)
P-value
Age 69.3 ± 8.8 66.2 ± 12.8 n.s.
Male sex 78.4% 74.8% n.s.
Smoking history 93% 90% n.s.
FEV1% predicted 88.8 ± 12.3 84.1 ± 0.4 n.s.
FEV1 (l) 2.24 ± 0.3 2.20 ± 0.59 n.s.
FVC% predicted 91.40 ± 12.01 94.59 ± 18.8 n.s.
FVC (l) 2.9146 ± 0.51 3.1350 ± 0.76 n.s.
DLCO% predicted 59.73 ± 14.34 65.53 ± 19.20 n.s.
Arterial basal pCO2 37.1 ± 2.6 38.3 ± 2.1 n.s.
Arterial basal pO2 79.1 ± 4.9 83.5 ± 3.8 n.s.
ILD: interstitial lung disease; FEV: forced expiratory value; FVC: forced
vital capacity; DLCO: diffusing capacity of the lung for carbon
monoxide; n.s.: not significant.







Pneumonectomy 4 (10.8%) 90 (12.3%) n.s.
Lobectomy 30 (81.1%) 528 (72.1%) n.s.
Sublobar resections 3 (8.1%) 114 (15.6%) n.s.
Histology
Adenocarcinoma 16 (43.2%) 428 (48%) n.s.
Squamous cell 13 (35.1%) 214 (29%) n.s.
Other 8 (21.6%) 96 (13%) n.s.
Stage I 16 (44%) 228 (33%) n.s.
Stage II 10 (28%) 252 (37%) n.s.
Stage III 7 (19.4%) 168 (24.6%) n.s.
Stage IV 3 (8.3%) 36 (5.3%) n.s.
ILD: interstitial lung disease; n.s.: not significant.
Table 3: Procedure-specific mortality and incidence of






Mean hospital stay 12.51 ± 5.5 9.58 ± 4.1 ≤0.01
Total deaths 3 (8.1%) 10 (1.4%) ≤0.01
Pneumonectomy 1/4 (25%) 3/90 (3.3%)
Lobectomy 2/30 (6.6%) 7/528 (1.3%)
Sublobar resection 0/3 0/114
ARDS/ALI 5 (13.5%) 17 (2.3%) ≤0.01
Pneumonectomy 1/4 (25%) 7/90 (7.8%)
Lobectomy 3/30 (10%) 8/528 (1.5%)
Sublobar resection 1/3 (33%) 2/114 (1.8%)
ILD: interstitial lung disease; ARDS: acute respiratory disease
syndrome; ALI: acute lung injury.








Prolonged air leak (≥1 week) 5 (13%) 112 (15%) 0.8
Pneumonia (fever and
culture positive)
2 (5%) 18 (2%) 0.2
BPF 1 (2%) 6 (≤1%) 0.2
Atelectasis (FBS) 2 (5%) 77 (10%) 0.3
ARDS/ALI 5 (13%) 17 (2.3%) ≤0.01
ILD: interstitial lung disease; BPF: bronchopleural fistula; FBS:
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Predictive factors for short-term outcome in
patients with ILD
In the ILD group, preoperative characteristics were compared
between patients who developed postoperative ARDS and those
who did not. ILD patients with postoperative ARDS had signifi-
cantly lower values of preoperative FVC% of predicted than
those without postoperative ARDS (77.8 ± 6.3 vs 93.6 ± 11.1%, re-
spectively; P < 0.001).
Furthermore, ILD patients with postoperative ARDS had sig-
nificantly lower values of preoperative DLCO% than those
without postoperative ARDS (47.6 ± 15.5 vs 61.9 ± 13.2%;
P < 0.001).
There was no significant difference in age, gender, smoking
history, other preoperative pulmonary function tests, pO2, pCO2,
extent of pulmonary resection, histological cell type, the stage of
NSCLC and type of ILD (idiopathic interstitial pneumonia [IP] vs
pneumoconiosis; see Section 3.5) between ILD patients with
postoperative ARDS and those without.
ILD patients with a preoperative FVC% of predicted >80% had
50% incidence of postoperative ALI/ARDS, while those with FVC
% of predicted >90% had no incidence.
Long-term outcome
In the ILD group, at the median follow-up of 26 months (range
4–119), 19 (51.3%) patients were still alive and 18 (48.7%)
patients had died. The most common cause of late death was re-
spiratory insufficiency due to the progression of fibrosis (n = 7;
38.9%), followed by the development of second primary lung
tumours (n = 4; 22.2%), tumour recurrence (n = 2; 11.1%) and
other (n = 2; 11.1%). In the control group, at the median follow-
up of 32 (range 3–120) months, 437 (60%) patients were still
alive and 301 (40%) had died. Differently from the ILD group,
the major cause of late death was tumour recurrence (local or
distant recurrence documented in at least 50% of patients who
had died).
The actuarial 5-year survival rate was 63 and 52%, and the
median survival was 47 ± 4.2 and 29 ± 5.4 months in patients
without and with ILD, respectively. Actuarial survival was signifi-
cantly worse in patients with ILD than in patients without ILD
(P = 0.019; Fig. 1).
In the ILD group, the actuarial 5-year survival rate was signifi-
cantly higher in patients with N0 disease (n = 24; 70% 5-year sur-
vival) than in patients with N1–N2 disease (n = 13; 12% 5-year
survival).
Outcome in patients with ILD related to
histopathology
The histological examination of the resected specimens of
patients with ILD showed that 19 (51.4%) patients had IP, includ-
ing 11 (29.8%) cases of idiopathic pulmonary fibrosis/usual inter-
stitial pneumonia (IPF/UIP) and 8 (21.6%) cases of non-specific
interstitial pneumonia, that was idiopathic in 4 (10.8%) patients
and related to collagen vascular disease in another 4 (10.8%)
patients. The remaining 18 patients had pneumoconiosis.
Among 5 patients with ILD who developed postoperative
ARDS, 3 had pneumoconiosis and 2 had IPF/UIP.
The Kaplan–Meier survival analysis showed no significant dif-
ference between patients affected by pneumoconiosis (n = 18)
and by IP (n = 19; Fig. 2).
Risk factors for late death in patients with ILD
No preoperative characteristics or operation data selected in the
univariable analysis (Table 5) were identified as predictors of late
death, according to Cox’s proportional hazard model (Table 6).
DISCUSSION
This study was undertaken to evaluate the role of surgery in
patients with concomitant lung cancer and ILD and to identify
predictive factors for survival following lung resection.
Our study differs from most others in the fact that only
patients with a preoperative diagnosis of ILD were included, with
12 of them already on steroid or immunosuppressive treatment
at the time of lung cancer resection and 49% of them complain-
ing of a Borg dyspnoea score II–III.
We found that patients with ILD present a significantly higher
incidence of postoperative ARDS (13.5 vs 2.3%; P < 0.01) and
consequently higher postoperative mortality (8.1 vs 1.4%;
P < 0.01) than those without ILD.
Figure 1: Survival curves after pulmonary resection for the non-ILD patients (n = 775) and the ILD patients (n = 37), (P = 0.019).
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Even the analysis of the outcome related to the specific surgi-
cal procedures showed a significantly higher postoperative mor-
tality for pneumonectomy (25 vs 3.3%; P < 0.01) and lobectomy
(6.6 vs 1.3%; P < 0.01) in patients with ILD, compared with
patients without ILD. In fact, the prognosis of postoperative
ARDS particularly in patients with ILD is extremely poor, with
mortality ranging from 50 to 100% [3–8]. In our study, 3 of the 5
ILD patients who developed postoperative ARDS died.
Excluding the study of Fujimoto et al. [6] showing no early
postoperative mortality in patients with IPF and lung cancer, the
incidence rates of postoperative morbidity and operative mortal-
ity are both significantly higher in patients with ILD, ranging
from 32 to 54% and from 8 to 18.2%, respectively [3–6]. In par-
ticular, patients with ILD seem to be more prone to develop
postoperative ARDS, with an incidence of 21–27% in several
series [3–5, 11].
It has also been recently suggested that acute exacerbation of
IPF may play a role in the pathophysiology of postoperative
ARDS [8] and that subpleural honeycombing on HRCT is an inde-
pendent risk factor for postoperative ARDS in patients without
clinical evidence of ILD [12], reinforcing the concept that patients
affected by ILD are at an increased risk of developing post-
operative ARDS.
The pathogenesis of postoperative ALI/ARDS is not well
understood, but it is likely that multiple influencing factors come
into play, including excessive perioperative fluid administration
[13], extent of resection [14], duration of operation [14], high-
inspired oxygen concentration with the production of reactive
oxygen species and capillary endothelial damage as a conse-
quence of haemodynamic shear stress [15].
In addition, one-lung ventilation (OLV), used during lung re-
section, is considered to be one of the most important causative
factors of postoperative ARDS, since the dependent lung is
exposed to barotrauma and volutrauma and there is a conspicu-
ous oxidative stress due to ischaemia–reperfusion resulting from
collapse and reinflation of the operative lung [16–18].
Lungs with pre-existing interstitial disease have less elastic
tissue and could therefore be more susceptible to volotrauma
and barotrauma. These data indicate that shortening the OLV
duration in patients with ILD may be useful in reducing the oc-
currence of postoperative ARDS.
We kept the time of OLV at a minimum in all patients with
ILD, resulting in a mean time of only 25 min (data not shown);
although we consider this an important prophylactic measure,
no conclusions about this aspect can be drawn.
Figure 2: Survival curves after pulmonary resection in patients affected by pneumoconiosis (n = 18) and by IP (n = 19), (P = n.s.).
Table 5: Univariate comparisons between patients with






Male sex 14 13 0.75
Age 68.8 ± 9.7 69 ± 7.1 0.96
Major co-morbidity 9 11 0.43
Procedure
Lobectomy 18 10 0.50
Histological type
Adenocarcinoma 9 6 0.31
Squamous cell carcinoma 5 7
Pathological stage
1 11 5 0.25
Type of ILD
IIP 10 7 0.73
Pneumoconiosis 9 8
Morbidity 6 5 0.92
Hospital stay 12.1 ± 6.4 11.7 ± 3 0.83
PaO2 78.4 ± 4.9 78.2 ± 6.8 0.92
PaCO2 36.6 ± 3.3 37.7 ± 1.4 0.3
FEV1 (l) 2.26 ± 0.43 2.25 ± 0.26 0.9
FEV1% 90.8 ± 14.9 84.2 ± 9.3 0.15
FVC (l) 3.02 ± 0.50 2.89 ± 0.48 0.44
FVC% 95.8 ± 12.4 89.4 ± 10 0.11
DLCO 61.7 ± 14.3 57.2 ± 15.6 0.42
DLCO/VA 72.5 ± 15.1 70.5 ± 22.4 0.78
ILD: interstitial lung disease; IIP: idiopathic interstitial pneumonia;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity;
DLCO: diffusing capacity of the lung for carbon monoxide; VA:
alveolar volume.
Table 6: Predictors of late death by multivariate Cox
regression analysis applied to patients with ILD
Variables HR (95% CI) P-value
FVC% 0.960 (0.889–1.036) 0.29
FEV1% 1.003 (0.924–1.088) 0.95
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; HR:
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The extent of resection has been consistently reported as a
risk factor for postoperative ARDS [14]. In this study, we found
that ILD patients undergoing pneumonectomy showed an inci-
dence rate of 25% of postoperative ARDS, although the extent of
resection was not a statistically significant risk factor, probably
because of the small sample size.
The patient who developed ARDS post pneumonectomy died,
while no ILD patient undergoing sublobar resection died.
Every staging tool, including Positron Emission Tomography,
Endobronchial Ultrasound, Endoscopic Ultrasound and video
mediastinoscopy, should be used in patients with ILD to better
define the extent of a complete resection before intervention, in
order to avoid operating on patients requiring a pneumonec-
tomy. On the other hand, a sublobar resection, when technically
feasible and oncologically appropriate, could be a good alterna-
tive to lobectomy in such high-risk patients.
The identification of risk factors for hospital mortality is then
crucial, in order to select ILD patients for lung surgery properly.
Several reports suggest that a number of physiological para-
meters are useful in assessing disease severity and predicting
survival in patients with ILD [19, 20]. To date, however, predicting
the occurrence of postoperative morbidity and mortality based
on preoperative baseline clinical variables has proved to be chal-
lenging [8–21]. A few studies have identified different prognostic
risk factors for postoperative ARDS, including low DLCO and
high preoperative composite physiological index [5], decreased
FVC [3] and pre-existing co-morbidities [11].
We could demonstrate in this study that, in ILD patients, lower
values of preoperative FVC% and DLCO% were both associated
with postoperative ARDS. ILD patients with a preoperative FVC%
of predicted <80% had 50% incidence of postoperative ALI/
ARDS, while those with FVC% of predicted >90% had no inci-
dence. The interpretation of the results of spirometry can be
confounded by the presence of concomitant ILD and emphyse-
ma (not rare in heavy smokers), which may lead to spurious
preservation of lung volumes [22]. Thus, the measurement of
DLCO% is particularly important in patients with ILD, since the
decreased diffusing capacity reflects the severity of ILD itself and
significantly increases the risk of developing postoperative ARDS.
Although late outcomes after lung resection are uniformly
worse in patients with ILD compared with patients without ILD,
long-term survival is still achievable in a super-selected group.
In this study, we observed a 5-year survival rate of 52% in
patients with ILD, which is within the range of survival rates
reported in the last 10 years. Saito et al. [7] showed a 5-year sur-
vival rate of 54.2% in patients with stage IA NSCLC and IPF, and
Watanabe et al. [8] showed a 5-year survival rate of 61.6% in
patients with IPF and stage IA and IB NSCLC. Chiyo et al. [4]
found a 5-year survival rate of 35.6%, with survival strongly
related to the nodal stage. For patients with potentially surgically
curable disease, lymph node metastasis is the most important
prognostic factor. As expected, we observed a significantly higher
5-year survival rate in ILD patients with N0 disease compared
with N1–N2 disease. However, only 13 patients had N1 (n = 8) or
N2 (n = 5) disease, making this analysis less meaningful. No pre-
dictors of long-term survival in the ILD group were identified in
the Cox proportional hazard model. Inasmuch as 7 (39%) patients
died due to the progression of fibrosis, this result could be related
to the fact that the ILD course in individual patients is highly vari-
able, and predicting the prognosis in individual patients is challen-
ging. We cannot also exclude a type II error. For instance, the FVC
% was associated in the univariate analysis with long-term survival
but failed to be a significant factor in the multivariable analysis. It
must also be considered that important variables like pneumon-
ectomy or N disease were not included in the univariate analysis
because they were represented with a number of less than five in
each subgroup. Of note, the 4 patients who had pneumonectomy
were dead at the time of the last follow-up.
In the ILD group, the most common cause of late death was
respiratory insufficiency due to the progression of fibrosis. Seven
patients with pulmonary fibrosis displayed a rapidly progressive
disease leading to respiratory failure and death with a mean
postoperative survival of only 14 (range 4–27) months. We
speculate that surgical trauma and mechanical ventilation would
have activated the progressive phase of fibrosis. On the other
hand, only 2 (11%) patients died of cancer recurrence, while at
least 50% of non-ILD patients died of cancer recurrence. These
results suggest that to improve the outcome in ILD patients,
strategies for preventing postoperative ARDS and the progression
of fibrosis should be implemented.
It has been shown that early administration of low-dose
methylprednisolone significantly reduces mortality from ARDS
after thoracic surgery [23]. In the long run, a balance should be
found between the utility of a steroid or immunosuppressive
therapy to control the progression of ILD and their side effects,
which could contribute to the development of a second primary
lung cancer (SPLC). Indeed, another important finding was the
high rate of development of an SPLC (4 patients) in the ILD
group. This event, in addition to the higher postoperative mor-
tality rate and chronic respiratory failure occurrence, might
explain the poorer long-term results compared with non-ILD
patients. For such a high rate of SPLC in ILD patients, an inten-
sive surveillance after curative pulmonary resection for lung
cancer has been advocated. Unfortunately, the treatment is
limited by the reduced pulmonary reserve. None of our 4 ILD
patients who developed an SPLC underwent surgery, because in
1 case the tumour was a small-cell lung cancer, and in the other
3 cases the pulmonary reserve was considered inadequate to
withstand a second resection. Even chemotherapy and/or radio-
therapy are of difficult application because both can contribute
to or determine the progression of fibrosis [24].
The prognostic value of different types of ILD after pulmonary
resection is unknown. The prognosis of IPF/UIP is generally the
worst among the ILD, with a median survival of only 2–3 years
from the diagnosis [25]. We did not find any significant differ-
ence in the long-term survival between patients with idiopathic
IP and with pneumoconiosis, although definitive conclusions
cannot be drawn from our findings because of the small sample
size. It is also possible that a longer follow-up could be necessary
to find a difference.
The limitations of this study are inherent to its retrospective
design, being susceptible to various sources of bias that may not
have been identified and controlled.
First of all, we acknowledged that all patients of this study
with ILD represent a selected group, as demonstrated by their
well-preserved pulmonary function. Patients with severe impair-
ment of pulmonary function were excluded from surgery. This
selection bias certainly has a significant impact on survival.
Secondly, our long-term results come from a survival analysis
based on a median follow-up of 26 months. However, since the
follow-up was 100% complete and the censoring in survival ana-
lysis was ‘non-informative’, our results would not have been
affected by such a follow-up. Finally, this is a single-institution
study and the limited sample size did not allow us to define
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some important aspects, such as the identification of the predic-
tors of long-term survival or the relative importance of the type
of ILD. These results should be confirmed by prospective studies
including larger series of patients.
In conclusion, major lung resection in patients with NSCLC
and ILD is associated with an increased postoperative morbidity
and mortality. Patients with a low preoperative FVC% should be
carefully assessed prior to undergoing surgery, particularly in the
presence of a lower DLCO%.
Long-term survival is significantly lower compared with
patients without ILD. Pneumonectomy is substantially contrain-
dicated in patients with ILD.
However, long-term survival is still achievable in a substantial
subgroup. Thus, surgery can be offered to appropriately selected
patients with lung cancer and ILD, keeping in mind the risk of
respiratory failure during the evaluation of such patients.
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